Prof. Dr. wenhu Liu | Pharmacology – professor at North sichuan medical college, China
Dr. Wenhu Liu is a distinguished biomedical researcher whose work bridges molecular biology and translational oncology, with a specialized focus on mechanisms of drug resistance in gastric cancer. Over more than a decade of academic service and scientific contribution, Dr. Liu has demonstrated unwavering commitment to unraveling the complexities of targeted cancer therapy, applying high-throughput proteomic technologies and pathway analysis. His insightful discoveries into resistance to trastuzumab and the role of intracellular signaling pathways have advanced the understanding of therapeutic challenges in oncology, making his research not only academically valuable but also clinically significant. Known for his analytical rigor and deep domain expertise, Dr. Liu continues to drive impactful research in the intersecting fields of cancer biology and pharmacoproteomics.
Profile Verified:
Education:
Dr. Liu obtained his doctoral degree in Biomedical Sciences from Chongqing University, a prestigious academic institution known for its multidisciplinary research excellence. During his studies from 2014 to 2017, he focused on integrative molecular techniques and the application of proteomics to cancer research. His academic training was grounded in both theoretical knowledge and practical research methodologies, allowing him to develop sophisticated skills in protein quantification, mass spectrometry, and biological validation. His Ph.D. research laid the foundation for his future contributions to understanding the molecular dynamics of chemotherapy resistance and cell signaling, culminating in a body of work that would later be recognized in peer-reviewed journals and institutional collaborations.
Experience:
Since July 2010, Dr. Liu has served at North Sichuan Medical University, where he has steadily progressed in his academic and research responsibilities. Over the years, he has led numerous research initiatives focused on therapeutic response in gastric and other cancers, particularly through the lens of proteomics. His work environment has provided him access to advanced laboratory infrastructure, multidisciplinary collaborators, and clinical case studies, enabling translational applications of his molecular findings. Dr. Liu’s dedication to both research and mentorship has had a positive ripple effect on the scientific community around him, nurturing early-career scientists while contributing novel insights to his field.
Research Interest:
Dr. Liu’s research interests lie at the intersection of cancer pharmacology, proteomics, and molecular signaling pathways. His main area of inquiry explores the biological mechanisms underlying resistance to HER2-targeted therapies, particularly trastuzumab. Utilizing label-free quantitative proteomics, his investigations delve into signaling cascades like Wnt/β-catenin and mTOR, aiming to identify predictive biomarkers and potential therapeutic targets. His work has significant implications for personalizing cancer treatment, overcoming resistance, and improving patient outcomes. Dr. Liu’s research is also guided by a vision to bridge basic science and clinical practice, using molecular data to inform real-world cancer therapy strategies.
Award:
Dr. Liu’s notable contributions have earned him institutional recognition, including a university-level commendation for research excellence. His scientific insight, particularly in elucidating trastuzumab resistance mechanisms through proteomic analysis, has been cited by peers and has drawn attention at national research symposia. Though still early in his accolades journey, his impactful publications and peer-reviewed assessments position him as a rising figure in biomedical research, meriting nomination for broader scientific awards. His growing body of work reflects both depth and relevance, marking him as an emerging leader in translational oncology.
Publications:
📘 Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer (2018, International Journal of Molecular Sciences) – Cited by 85 articles.
🧪 Quantitative Proteomics Profiling Reveals Activation of mTOR Pathway in Trastuzumab Resistance (2019, Proteomics Insights) – Cited by 42 articles.
Conclusion:
Dr. Wenhu Liu exemplifies the core values of research excellence through his consistent contributions to the molecular understanding of cancer drug resistance. His blend of advanced proteomic techniques, detailed pathway analyses, and translational objectives demonstrates both innovation and scientific responsibility. Although still expanding his global footprint in terms of collaborations and grant leadership, Dr. Liu’s current body of work positions him well for recognition in competitive scientific arenas. His research has begun to shape future directions in precision oncology and molecular pharmacology, making him a highly deserving nominee for the “Excellence in Research” award. With a foundation of high-impact publications, an active role in peer review, and a focused academic vision, Dr. Liu is poised to continue driving meaningful advances in biomedical science.